NCT06044623 - Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients | Biotech Hunter

Enrollment

495

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

October 31, 2028

Study Completion Date

May 31, 2029

Conditions

Metastatic Breast CancerAdvanced Breast CancerQuality of LifeToxicityOlder Patients

Interventions

DRUG

CDK 4/6 inhibitors

Either Palbociclib, Ribociclib or Abemaciclib

DRUG

Endocrine therapy

Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor

Trial Locations (12)

NOT_YET_RECRUITING

Department of Oncology, Uppsala University Hospital, Uppsala

RECRUITING

Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki

NOT_YET_RECRUITING

Fourth Oncology Department & Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens

NOT_YET_RECRUITING

Second Department of Medical Oncology, Hygeia Hospital, Athens

NOT_YET_RECRUITING

Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Pátrai

NOT_YET_RECRUITING

Medical Oncology Unit, S. Andrew Hospital, Pátrai

NOT_YET_RECRUITING

Second Department of Medical Oncology, Euromedica General Clinic, Thessaloniki

NOT_YET_RECRUITING

Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence

NOT_YET_RECRUITING

"Sandro Pitigliani Department of Medical Oncology, Hospital of Prato", Prato

NOT_YET_RECRUITING

Department of Oncology, Akershus University Hospital (AHUS), Oslo

NOT_YET_RECRUITING

Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona

RECRUITING

Department of Oncology, Örebro University Hospital, Örebro